IDEAYA Biosciences Advances Precision Oncology with AI Discovery

IDEAYA Biosciences (IDYA) is strengthening its position in the biotechnology sector, specializing in synthetic lethality-based cancer therapies. Wedbush Securities increased its price target for IDEAYA from $52 to $58 following positive Phase 2/3 OptimUM-02 trial results. The company is also advancing its IDE574 program, an early-stage clinical trial for a first-in-class small-molecule therapy targeting epigenetic markers critical for cancer cell survival, and uses AI for drug discovery.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin